Orexo welcomes increased access to treatment for patients with opioid dependence in the US
2016年7月7日 - 3:27PM
ビジネスワイヤ(英語)
Regulatory News:
Uppsala, Sweden – July 7, 2016 – Orexo AB applauds the
Administration’s announcement yesterday to increase access to the
treatment of opioid dependence in the US, by increasing the cap on
the number of patients that can be treated by physicians from 100
to 275, starting 30 days after publication in the Federal Register.
Additionally, we commend the strong bipartisan Congressional
support of this announcement. We look forward to Congress passing
additional legislation further supporting increased access to
appropriate patient care.
More than 5 million US citizens are misusing opioids and at
least 2 million are opioid dependent. Today about 640,000 patients
are in treatment with buprenorphine. Many struggle to find a
qualified physician due to the patient cap which has been a
significant hurdle in many regions of the US. In several instances,
the lack of access to a qualified physician has led to a vicious
cycle forcing patients to obtain their treatment on the street in a
drug abusing environment perpetuating the risk of continued
addiction.
Orexo strongly believes that medication assisted treatment with
buprenorphine containing products, prescribed by a qualified
physician should be used as part of a comprehensive treatment plan,
which includes counseling and psychosocial support. With the
initiative announced, opioid dependence treatment takes an
important step towards open and affordable access to treatment in
an appropriate clinical setting.
“I am encouraged by the initiative announced, which will be a
significant change for many patients suffering from opioid
dependence and save lives. For Orexo and our product Zubsolv® this
change will be important for our continued sales and market share
growth. I am proud of the incredible efforts our US team has made
in Washington DC during the last 12 months to support the
legislators and government with information and knowledge leading
to this game changing decision for patients, physicians and for
Orexo” said Nikolaj Sørensen, CEO and President of Orexo
AB.
About Orexo
Orexo is a specialty pharmaceutical company commercializing its
proprietary product Zubsolv® for treatment of opioid dependence in
the US. Zubsolv is an advanced formulation of buprenorphine and
naloxone using Orexo’s unique knowledge and expertise in sublingual
drug delivery. R&D is focusing on reformulation of known
substances to new improved products that meet great unmet medical
needs by using its patented proprietary technologies. Orexo’s
share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and
is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global
headquarters and R&D are based in Uppsala, Sweden.
For more information about Orexo and Zubsolv, please visit
www.orexo.com and www.zubsolv.com.
This is information is information that Orexo AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact persons set out above, at 8.00 am CET on July 7,
2016.
This information was brought to you by Cision
http://news.cision.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160706006454/en/
Orexo AB (publ.)Nikolaj Sørensen, +46 (0)18 780 88 00CEO
and Presidentir@orexo.com
Orefinders Resources (TSXV:ORX)
過去 株価チャート
から 11 2024 まで 12 2024
Orefinders Resources (TSXV:ORX)
過去 株価チャート
から 12 2023 まで 12 2024